Skip to main content

Table 1 Patient demographics at baseline

From: Tolerance and rebound with zafirlukast in patients with persistent asthma

  β2-agonists + Placebo (N = 7) β2-agonists + Zafirlukast (N = 14) ICS-treated + Placebo (N = 8) ICS-treated + Zafirlukast (N = 16)
Sex, male/female 3/4 8/6 2/6 9/7
Age, years 29 (21–55) 42 (21–69) 45 (30–65) 37 (19–65)
Ex-smoker 2 4 5 6
FEV1, L 2.7 (2.3–3.7) 2.1 (1.4–4.2) 2.8 (2.0–3.8) 2.7 (1.4–4.1)
Baseline FEV1, % predicted 80 (65–102) 85 (69–107) 76 (60–95) 77 (56–98)
Inhaled corticosteroid, μg/day NA NA 1600 (1000–2400) 1600 (1000–2400)
PD20 methacholine, μg * 0.008 (0.001–0.04) 0.04 (0.005–1.3) 0.03 (0.004–0.2) 0.02 (0.001–0.6)
  1. Data are given as median and (range) except * geometric mean and (range). NA not applicable